{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:11:43Z","timestamp":1775279503997,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Kaposi sarcoma (KS) is a mesenchymal malignancy induced by human herpes virus-8 (HHV-8). Whilst combined anti-retroviral therapy (cART) has substantially reduced the incidence of KS in people living with HIV (PLWH), KS remains the commonest neoplasia in this population. In up to 15\u201320% of cases, KS fails to respond to cART. T-cells immune exhaustion is thought to play a central role in mediating KS development and progression in PLWH receiving cART. The high reliance of PD-1 in shaping the cART-refractory phenotype poses a strong rationale for the use of PD-1 blocking antibodies against KS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>StarKap is a phase Ib, open label, single arm study aiming at evaluating the safety, tolerability of dostarlimab- an anti PD-1 antibody- in cART-refractory KS. Secondary endpoint is the evaluation of overall response rates by AIDS Clinical Trial Group (ACTG) criteria complemented by RECIST v1.1 in patients with visceral disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The trial will enrol 20 patients in total. After completion of the screening procedures, participants will receive the first dose of dostarlimab within 28\u00a0days. Dostarlimab will be administered at the dose of 500\u00a0mg evry 3\u00a0weeks for the first 5 cycles, and at 1000\u00a0mg every 6\u00a0weeks thereafter. Treatment will continue until disease progression, unacceptable toxicity, or completion of 1\u00a0year of treatment. The first 6 patients will be enrolled in a safety-lead-in phase, if no dose-limiting toxicities (DLTs) will occur within the 21\u00a0days in the first 6 participants, trial will continue. Patients will be monitored for the emergence of adverse events until 90\u00a0days after the last dose of treatment. Tumour response will be assessed as objective response rate (ORR) at cycle 4, cycle 8 and end of treatment. Tissue, bloods, and stool samples will be collected at baseline, on treatment and at end of treatment to satisfy the related translation plan.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14326-2","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:16:40Z","timestamp":1751354200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi\u2019s Sarcoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Claudia A. M.","family":"Fulgenzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Dalla Pria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto Giovanni","family":"Leone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena Ferrer Martinez","family":"Del Peral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Eleanor","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"14326_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","volume":"378","author":"R Yarchoan","year":"2018","unstructured":"Yarchoan R, Uldrick TS. HIV-Associated Cancers and Related Diseases. N Engl J Med. 2018;378:1029\u201341.","journal-title":"N Engl J Med"},{"key":"14326_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2018.12.036","volume":"114","author":"C Lebbe","year":"2019","unstructured":"Lebbe C, Garbe C, Stratigos AJ, Harwood C, Peris K, Marmol VD, Malvehy J, et al. Diagnosis and treatment of Kaposi\u2019s sarcoma: European consensus-based interdisciplinary guideline (EDF\/EADO\/EORTC). Eur J Cancer. 2019;114:117\u201327.","journal-title":"Eur J Cancer"},{"key":"14326_CR3","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1200\/JCO.2016.69.3812","volume":"34","author":"MN Polizzotto","year":"2016","unstructured":"Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Bevans M, Sereti I, et al. Pomalidomide for Symptomatic Kaposi\u2019s Sarcoma in People With and Without HIV Infection: A Phase I\/II Study. J Clin Oncol. 2016;34:4125\u201331.","journal-title":"J Clin Oncol"},{"key":"14326_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/imr.12823","volume":"292","author":"C Fenwick","year":"2019","unstructured":"Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, Pantaleo G. T-cell exhaustion in HIV infection. Immunol Rev. 2019;292:149\u201363.","journal-title":"Immunol Rev"},{"key":"14326_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/QAD.0000000000000222","volume":"28","author":"P Morlat","year":"2014","unstructured":"Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, Georget A, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28:1181\u201391.","journal-title":"AIDS"},{"key":"14326_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.virol.2019.07.024","volume":"536","author":"J Chen","year":"2019","unstructured":"Chen J, Del Valle L, Lin HY, Plaisance-Bonstaff K, Forrest JC, Post SR, Qin Z. Expression of PD-1 and PD-Ls in Kaposi\u2019s sarcoma and regulation by oncogenic herpesvirus lytic reactivation. Virology. 2019;536:16\u20139.","journal-title":"Virology"},{"key":"14326_CR7","doi-asserted-by":"publisher","first-page":"72961","DOI":"10.18632\/oncotarget.12150","volume":"7","author":"A Beldi-Ferchiou","year":"2016","unstructured":"Beldi-Ferchiou A, Lambert M, Dogniaux S, Vely F, Vivier E, Olive D, Dupuy S, et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget. 2016;7:72961\u201377.","journal-title":"Oncotarget"},{"key":"14326_CR8","doi-asserted-by":"publisher","first-page":"e1304337","DOI":"10.1080\/2162402X.2017.1304337","volume":"6","author":"S Mletzko","year":"2017","unstructured":"Mletzko S, Pinato DJ, Robey RC, Dalla Pria A, Benson P, Imami N, Bower M. Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi\u2019s sarcoma: A pilot study. Oncoimmunology. 2017;6:e1304337.","journal-title":"Oncoimmunology"},{"key":"14326_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(22)00097-3","volume":"23","author":"J Delyon","year":"2022","unstructured":"Delyon J, Biard L, Renaud M, Resche-Rigon M, Le Goff J, Dalle S, Heidelberger V, et al. PD-1 blockade with pembrolizumab in classic or endemic Kaposi\u2019s sarcoma: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2022;23:491\u2013500.","journal-title":"Lancet Oncol"},{"key":"14326_CR10","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.annonc.2022.03.012","volume":"33","author":"A Zer","year":"2022","unstructured":"Zer A, Icht O, Yosef L, Avram D, Jacobi O, Fenig E, Kurman N, et al. Phase II single-arm study of nivolumab and ipilimumab (Nivo\/Ipi) in previously treated classical Kaposi sarcoma (cKS). Ann Oncol. 2022;33:720\u20137.","journal-title":"Ann Oncol"},{"key":"14326_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1200\/JCO.24.00640","volume":"43","author":"K Lurain","year":"2025","unstructured":"Lurain K, Ramaswami R, Ekwede I, Eulo V, Goyal G, Menon M, Odeny TA, et al. Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma. J Clin Oncol. 2025;43:432\u201342.","journal-title":"J Clin Oncol"},{"key":"14326_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/cncr.35110","volume":"130","author":"L Rajdev","year":"2024","unstructured":"Rajdev L, Jackie Wang CC, Joshi H, Lensing S, Lee J, Ramos JC, Baiocchi R, et al. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study. Cancer. 2024;130:985\u201394.","journal-title":"Cancer"},{"key":"14326_CR13","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","volume":"6","author":"M Gonzalez-Cao","year":"2020","unstructured":"Gonzalez-Cao M, Moran T, Dalmau J, Garcia-Corbacho J, Bracht JWP, Bernabe R, Juan O, et al. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study. JAMA Oncol. 2020;6:1063\u20137.","journal-title":"JAMA Oncol"},{"key":"14326_CR14","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1200\/JCO.22.02459","volume":"41","author":"T El Zarif","year":"2023","unstructured":"El Zarif T, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, et al. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023;41:3712\u201323.","journal-title":"J Clin Oncol"},{"key":"14326_CR15","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza MR, Chase DM, Slomovitz BM, dePont CR, Novak Z, Black D, Gilbert L, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388:2145\u201358.","journal-title":"N Engl J Med"},{"issue":"1","key":"14326_CR16","doi-asserted-by":"publisher","first-page":"e003777","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"A Oaknin","year":"2022","unstructured":"Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777.","journal-title":"J Immunother Cancer"},{"key":"14326_CR17","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1017\/cts.2024.599","volume":"8","author":"N Li","year":"2024","unstructured":"Li N, Zhou X, Yan D. Phase I clinical trial designs in oncology: A systematic literature review from 2020 to 2022. J Clin Transl Sci. 2024;8:e134.","journal-title":"J Clin Transl Sci"},{"key":"14326_CR18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1126\/science.1223490","volume":"336","author":"LV Hooper","year":"2012","unstructured":"Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336:1268\u201373.","journal-title":"Science"},{"key":"14326_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/QAD.0000000000000511","volume":"29","author":"M Somsouk","year":"2015","unstructured":"Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, Martin JN, et al. Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS. 2015;29:43\u201351.","journal-title":"AIDS"},{"key":"14326_CR20","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/mi.2014.107","volume":"8","author":"JF Vazquez-Castellanos","year":"2015","unstructured":"Vazquez-Castellanos JF, Serrano-Villar S, Latorre A, Artacho A, Ferrus ML, Madrid N, Vallejo A, et al. Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol. 2015;8:760\u201372.","journal-title":"Mucosal Immunol"},{"key":"14326_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97\u2013103.","journal-title":"Science"},{"key":"14326_CR22","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2326-6066.CIR-18-0121","volume":"6","author":"N Galanina","year":"2018","unstructured":"Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunol Res. 2018;6:1129\u201335.","journal-title":"Cancer Immunol Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14326-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14326-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14326-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:16:41Z","timestamp":1751354201000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14326-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14326"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14326-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the London South East NHS Ethics Committee, the UK Medicines and Healthcare products Regulatory Agency and the UK Health Research Authority (IRAS ID 1004389). The study is performed in compliance with the declaration of Helsinki and the principles of Good Clinical Practice. Signed informed consent is obtained from each patient before study entry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DJP received lecture fees from ViiV Healthcare, Bayer Healthcare, BMS, Roche, Eisai, Falk Foundation, travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, DaVolterra, Mursla, Exact Sciences and Astra Zeneca; research funding (to institution) from MSD, GSK and BMS. CAMF received lecture fees from EISAI and AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1104"}}